Skip to main content
Erschienen in: Herz 6/2019

15.02.2018 | Original articles

Cognitive performance of patients with chronic heart failure on sacubitril/valsartan

A retrospective cohort study

verfasst von: Dr. R. De Vecchis, MD, C. Ariano, G. Di Biase, M. Noutsias

Erschienen in: Herz | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Sacubitril, a neprilysin inhibitor in the combination molecule sacubitril/valsartan, slows down degradation of endogenous natriuretic peptides, thereby enhancing their beneficial cardiovascular effects. However, sacubitril might also promote neuronal dysfunction and cognitive impairment in patients with chronic heart failure (CHF) treated with sacubitril/valsartan, due to possible neprilysin inhibition at the level of Central Nervous System.

Methods

A retrospective cohort study was undertaken to detect the effects exerted by sacubitril/valsartan on cognitive function in CHF patients. The patients’ clinical data were examined for information provided in the Mini-Mental State Examination (MMSE), which was routinely administered during clinical visits at two centers from 15 March to 31 October 2017. Patients in the sacubitril/valsartan group had a clinical history of at least 3 months of continuous sacubitril/valsartan administration. The control group comprised CHF patients on conventional therapy not taking sacubitril/valsartan. In the between-group comparison, patients were matched for mean age, educational level, sex, NYHA class, and comorbidities. In the present retrospective study only patients in NYHA class II-III were enrolled.

Results

The mean MMSE score was 22.72 ± 2.68 (mean ± standard deviation [SD]) in the sacubitril/valsartan group (n = 51 patients) vs. 21.96 ± 2.73 (mean ± SD) in the control group (n = 51; p = 0.1572, independent samples t-test). Thus, a similar mild-to-moderate impairment in cognitive performance was found in the comparison between the two groups.

Conclusion

In our study, we did not find any evidence of the alleged harmful influence of sacubitril/valsartan on cognitive function. Patients taking sacubitril/valsartan for at least 3 months had similar mean MMSE scores to control subjects.
Literatur
1.
Zurück zum Zitat Campbell DJ (2017) Long-term neprilysin inhibition—implications for ARNIs. Nat Rev Cardiol 14(3):171–186CrossRefPubMed Campbell DJ (2017) Long-term neprilysin inhibition—implications for ARNIs. Nat Rev Cardiol 14(3):171–186CrossRefPubMed
2.
Zurück zum Zitat McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004CrossRefPubMed
4.
Zurück zum Zitat Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP (2009) Hersh LB Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer’s disease. J Neurosci Res 87(6):1462–1473CrossRefPubMedPubMedCentral Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP (2009) Hersh LB Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer’s disease. J Neurosci Res 87(6):1462–1473CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kanemitsu H, Tomiyama T, Mori H (2003) Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350:113–116CrossRefPubMed Kanemitsu H, Tomiyama T, Mori H (2003) Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350:113–116CrossRefPubMed
6.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefPubMed Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefPubMed
7.
Zurück zum Zitat van der Velpen IF, Yancy CW, Sorond FA, Sabayan B (2017) Impaired cardiac function and cognitive brain aging. Can J Cardiol 33(12):1587–1596CrossRefPubMed van der Velpen IF, Yancy CW, Sorond FA, Sabayan B (2017) Impaired cardiac function and cognitive brain aging. Can J Cardiol 33(12):1587–1596CrossRefPubMed
8.
Zurück zum Zitat van Buchem MA, Biessels GJ, Brunner la Rocca HP, de Craen AJ, van der Flier WM, Ikram MA, Kappelle LJ, Koudstaal PJ, Mooijaart SP, Niessen W, van Oostenbrugge R, de Roos A, van Rossum AC, Daemen MJ (2014) The heart-brain connection: a multidisciplinary approach targeting a missing link in the pathophysiology of vascular cognitive impairment. J Alzheimers Dis 42(Suppl 4):S443–S451CrossRefPubMed van Buchem MA, Biessels GJ, Brunner la Rocca HP, de Craen AJ, van der Flier WM, Ikram MA, Kappelle LJ, Koudstaal PJ, Mooijaart SP, Niessen W, van Oostenbrugge R, de Roos A, van Rossum AC, Daemen MJ (2014) The heart-brain connection: a multidisciplinary approach targeting a missing link in the pathophysiology of vascular cognitive impairment. J Alzheimers Dis 42(Suppl 4):S443–S451CrossRefPubMed
9.
Zurück zum Zitat Ogoh S (2017) Relationship between cognitive function and regulation of cerebral blood flow. J Physiol Sci 67(3):345–351CrossRefPubMed Ogoh S (2017) Relationship between cognitive function and regulation of cerebral blood flow. J Physiol Sci 67(3):345–351CrossRefPubMed
10.
Zurück zum Zitat Čelutkienė J, Vaitkevičius A, Jakštienė S, Jatužis D (2016) Expert opinion-cognitive decline in heart failure: more attention is needed. Card Fail Rev 2(2):106–109PubMedPubMedCentral Čelutkienė J, Vaitkevičius A, Jakštienė S, Jatužis D (2016) Expert opinion-cognitive decline in heart failure: more attention is needed. Card Fail Rev 2(2):106–109PubMedPubMedCentral
11.
Zurück zum Zitat Debette S, Bauters C, Leys D, Lamblin N, Pasquier F, de Groote P (2007) Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail 13(4):205–208CrossRefPubMed Debette S, Bauters C, Leys D, Lamblin N, Pasquier F, de Groote P (2007) Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail 13(4):205–208CrossRefPubMed
12.
Zurück zum Zitat Dodson JA, Truong TT, Towle VR, Kerins G, Chaudhry SI (2013) Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. Am J Med 126(2):120–126CrossRefPubMedPubMedCentral Dodson JA, Truong TT, Towle VR, Kerins G, Chaudhry SI (2013) Cognitive impairment in older adults with heart failure: prevalence, documentation, and impact on outcomes. Am J Med 126(2):120–126CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Levin SN, Hajduk AM, McManus DD, Darling CE, Gurwitz JH, Spencer FA, Goldberg RJ, Saczynski JS (2014) Cognitive status in patients hospitalized with acute decompensated heart failure. Am Heart J 168(6):917–923CrossRefPubMedPubMedCentral Levin SN, Hajduk AM, McManus DD, Darling CE, Gurwitz JH, Spencer FA, Goldberg RJ, Saczynski JS (2014) Cognitive status in patients hospitalized with acute decompensated heart failure. Am Heart J 168(6):917–923CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Spencer B, Marr RA, Gindi R, Potkar R, Michael S, Adame A, Rockenstein E, Verma IM, Masliah E (2011) Peripheral delivery of a CNS targeted, metallo-protease reduces aβ toxicity in a mouse model of Alzheimer’s disease. PLoS ONE 6(1):e16575–31CrossRefPubMedPubMedCentral Spencer B, Marr RA, Gindi R, Potkar R, Michael S, Adame A, Rockenstein E, Verma IM, Masliah E (2011) Peripheral delivery of a CNS targeted, metallo-protease reduces aβ toxicity in a mouse model of Alzheimer’s disease. PLoS ONE 6(1):e16575–31CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park JS, Bae JS (2013) Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer’s disease mice. Brain Res 1529(5):113–124CrossRefPubMed Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park JS, Bae JS (2013) Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer’s disease mice. Brain Res 1529(5):113–124CrossRefPubMed
16.
Zurück zum Zitat Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, Jhee S, Gevorkyan H, Rajman I (2016) The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81(5):878–890CrossRefPubMedPubMedCentral Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, Jhee S, Gevorkyan H, Rajman I (2016) The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81(5):878–890CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, Buono C, Zhou W, DeCristofaro M, Douville J, Goodrich GG, Mansfield K, Saravanan C, Cumin F, Webb RL, Bateman RJ (2017) The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. Toxicol Appl Pharmacol 323(15):53–65CrossRefPubMed Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, Buono C, Zhou W, DeCristofaro M, Douville J, Goodrich GG, Mansfield K, Saravanan C, Cumin F, Webb RL, Bateman RJ (2017) The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. Toxicol Appl Pharmacol 323(15):53–65CrossRefPubMed
18.
Zurück zum Zitat Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. Jacc Heart Fail 5(7):471–482CrossRefPubMed Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV (2017) Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. Jacc Heart Fail 5(7):471–482CrossRefPubMed
19.
Zurück zum Zitat Iskandar ZM, Lang CC (2017) Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients. Drugs Today 53(10):545–551CrossRef Iskandar ZM, Lang CC (2017) Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients. Drugs Today 53(10):545–551CrossRef
Metadaten
Titel
Cognitive performance of patients with chronic heart failure on sacubitril/valsartan
A retrospective cohort study
verfasst von
Dr. R. De Vecchis, MD
C. Ariano
G. Di Biase
M. Noutsias
Publikationsdatum
15.02.2018
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 6/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-018-4683-5

Weitere Artikel der Ausgabe 6/2019

Herz 6/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.